Quick Answer
Keros Therapeutics, Inc. reported Diluted EPS of $2.30 per share for fiscal year 2025.
Keros Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $2.30 | +146.0% |
| 2024 | -$5.00 | +3.8% |
| 2023 | -$5.20 | -25.3% |
| 2022 | -$4.15 | -64.7% |
| 2021 | -$2.52 | +14.0% |
| 2020 | -$2.93 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.18 | +87.2% | +76.3% |
| June 30, 2025 | -$0.76 | +39.2% | -121.0% |
| March 31, 2025 | $3.62 | +399.2% | +356.7% |
| September 30, 2024 | -$1.41 | -6.0% | -12.8% |
| June 30, 2024 | -$1.25 | +1.6% | -3.3% |
| March 31, 2024 | -$1.21 | +4.0% | +9.0% |
| September 30, 2023 | -$1.33 | -44.6% | -4.7% |
| June 30, 2023 | -$1.27 | -12.4% | -0.8% |
- Keros Therapeutics, Inc. showed an increase of +146.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Keros Therapeutics, Inc.’s diluted eps has grown by 178.5% (from $2.93 per share (loss) to $2.30 per share).
- The most recent figure is from Keros Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: